A Guide to Mounjaro for the Treatment of Type 2 Diabetes Mellitus 
Paige Willms
Abstract
Type 2 diabetes mellitus is the most common type of diabetes. There are currently a variety of medications available for the treatment of the disease state. Mounjaro (tirzepatide) is an innovative medication that is the first in its class for the treatment of type 2 diabetes. Mounjaro is a once weekly injection that has been shown to improve outcomes of Type 2 diabetes. Mounjaro is a Glucagon-Like Peptide 1/Glucose-dependent insulinotropic polypeptide (GLP-1/GIP) co-agonist and has been shown to lower hemoglobin A1C in combination with diet and exercise. It has also been shown to cause weight loss in patients with type 2 diabetes.
Full Text
Vol 7 Article 2
File Size: 193 kb
File Type: pdf
Download File

Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.

Subscribe to ARxCH